Maurice Zauderer
Affiliations: | University of Rochester, Rochester, NY |
Area:
Oncology, Immunology, Molecular BiologyGoogle:
"Maurice Zauderer"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Greengard E, Williams R, Moriarity B, et al. (2024) A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614). Pediatric Blood & Cancer. e30938 |
| Smith ES, Balch LA, Scrivens M, et al. (2023) Use of poxvirus display to select antibodies specific for complex membrane antigens. Mabs. 15: 2249947 |
| Klenk C, Scrivens M, Niederer A, et al. (2023) A Vaccinia-based system for directed evolution of GPCRs in mammalian cells. Nature Communications. 14: 1770 |
| Shafique M, Fisher TL, Evans EE, et al. (2021) A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Kharkwal SS, Johndrow CT, Veerapen N, et al. (2021) Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T Cell Engagers Generates Anti-Tumor Immunity While Avoiding Anergy. Cancer Research |
| Shafique MR, Fisher TL, Evans EE, et al. (2020) Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies. Journal of Clinical Oncology. 38: 75-75 |
| Ruffolo LI, Ullman NA, Dale B, et al. (2020) Antibody blockade of semaphorin 4D to sensitize pancreatic cancer to immune checkpoint blockade. Journal of Clinical Oncology. 38: 26-26 |
| Shafique MR, Fisher TL, Evans EE, et al. (2020) Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. Journal of Clinical Oncology. 38: 3011-3011 |
| Evans EE, Lesinski GB, Fisher TL, et al. (2020) Abstract A15: Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors Clinical Cancer Research. 26 |
| Das R, Guan P, Wiener SJ, et al. (2019) Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein. Blood Advances. 3: 813-824 |